SCRI Tissue Testing Registry

Stopped early

Conditions studied: Melanoma, Myelodysplastic Syndrome, Multiple Myeloma, Lymphoma

In brief

Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date. Future testing may include assays for newly identified markers of potential prognostic and/or therapeutic value. These markers may be specific to an individual cancer type, or they may be present more generally in cancer and/or other conditions.

Key facts

Study ID

NCT00965861

Run by

SCRI Development Innovations, LLC

People needed

20

Starts

2010-05-01

Expected to finish

2013-02-01

Last updated by the study team

2013-08-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must be >= 18 years of age.
• Patients must be able to provide written informed consent.

You may not qualify if…

• Not Applicable

Where it is running

• Tennessee Oncology, PLLC — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.